MBX Biosciences, Inc (MBX) insider trading

Every open-market stock purchase and sale by MBX Biosciences, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • Salomon Azoulay (C-suite exec) sold $24.3K in the last 90 days.
  • Last insider buy: P. Kent Hawryluk (CEO), $526K, 7 months ago.

Last 12 months: insiders bought $526K (1 buy) and sold $2.7M (4 sales). Last close $50.46 on Oct 22, 2026.

Recent MBX insider trades

DateInsiderTradeValue
Oct 20, 2026Peter Radovich (Insider)Bought (not open market)—
Aug 4, 2026Salomon Azoulay (C-suite exec)Sold$24.3K
Aug 3, 2026John W Smither (CFO)Bought (not open market)—
Aug 3, 2026John W Smither (CFO)Bought (not open market)—
Aug 3, 2026Steven L. Hoerter (CEO)Bought (not open market)—
Aug 3, 2026Steven L. Hoerter (CEO)Bought (not open market)—
Jun 4, 2026Edward T Mathers (Insider)Bought (not open market)—
Jun 4, 2026Patrick J Heron (Insider)Bought (not open market)—
Jun 4, 2026Tiba Aynechi (Insider)Bought (not open market)—
Jun 4, 2026Steven L. Hoerter (Insider)Bought (not open market)—
Jun 4, 2026Steven Ryder (Insider)Bought (not open market)—
Jun 4, 2026Laurie Stelzer (Insider)Bought (not open market)—
Jun 4, 2026Ora H. Pescovitz (Insider)Bought (not open market)—
May 8, 2026Salomon Azoulay (C-suite exec)Sold$2.1M
May 8, 2026Salomon Azoulay (C-suite exec)Sold$575K
May 8, 2026Salomon Azoulay (C-suite exec)Bought (not open market)—
May 8, 2026Salomon Azoulay (C-suite exec)Bought (not open market)—
May 6, 2026P. Kent Hawryluk (CEO)Sold$17.9K
May 6, 2026Salomon Azoulay (C-suite exec)Sold$6.8K
May 1, 2026Steven L. Hoerter (Insider)Bought (not open market)—
May 1, 2026Steven L. Hoerter (Insider)Bought (not open market)—
Mar 13, 2026P. Kent Hawryluk (CEO)Bought$526K
Feb 26, 2026P. Kent Hawryluk (CEO)Bought (not open market)—
Feb 2, 2026Richard Bartram (CFO)Bought (not open market)—
Feb 2, 2026Salomon Azoulay (C-suite exec)Bought (not open market)—

Who's trading MBX

Get free alerts when an insider at MBX Biosciences, Inc files a new trade →